Single dose pharmacokinetics of piroxicam in cats

Journal of Veterinary Pharmacology and Therapeutics

Volumn 26, Issue 4, 2003, Pages 259-263

  Heeb, Heather L ^a   Chun, R ^a   Koch, D E ^a   Goatley, M A ^a   Hunter, R P ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG ABSORPTION; MALE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; CATS; CROSS-OVER STUDIES; INFUSIONS, INTRAVENOUS; MALE; PIROXICAM;

ANIMALIA; CANIS FAMILIARIS; FELIS CATUS;

EID: 0043162119     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2885.2003.00479.x     Document Type: Article

References (29)

1. Earnest, D.L., Hixson, L.J. & Alberts, D.S. (1992) Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. Journal of Cellular Biochemistry, Supplement 161, 156-166.
2. Fernandez-Troconiz, J.I., Lopez-Bustamante, L.G. & Fos, D. (1991) Pharmacokinetics of piroxicam in rats. European Journal of Drug Metabolism and Pharmacokinetics, 3, 80-84.
3. Galbraith, E.A. & McKellar, Q.A. (1991) Pharmacokinetics and pharmacodynamics of piroxicam in dogs. Veterinary Record, 128, 561-565.
4. Gibaldi, M. & Perrier, P. (1982). Pharmacokinetics, 2nd edn. Marcel Dekker, NY, USA.
5. Hixson, L.J., Alberts, D.S., Krutzsch, M. et al. (1994) Antiproliferative effect of nonsteroidal anti-inflammatory drugs against human colon cancer cells. Cancer Epidemiology, Biomarkers & Prevention, 3, 433-438.
6. Hobbs, D.C. (1983) Pharmacokinetics of piroxicam in man. European Journal of Rheumatology and Inflammation, 6, 46-55.
7. Hunter, R.P., Lynch, M.J., Ericson, J.F., Millas, W.J., Fletcher, A.M., Ryan, N.I. & Olson, J.A. (1995) Pharmacokinetics, oral bioavailability and tissue distribution of azithromycin in cats. Journal of Veterinary Pharmacology and Therapeutics, 18, 38-46.
8. Joseph, N.J., Lakshmi, S. & Jayakrishnan, A. (2002) A floating-type oral dosage form for piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in rabbits. Journal of Controlled Release, 79, 71-79.
9. Kelloff, G.J., Boone, C.W., Crowell, J.A., Steele, V.E., Lubet, R. & Sigman, C.C. (1994a) Chemopreventative drug development: perspectives and progress. Cancer Epidemiology, Biomarkers & Prevention, 3, 85-98.
10. Kelloff, G.J., Crowell, J.A., Boone, C.W. et al. (1994b) Strategy and planning for chemopreventive drug development: clinical development plans. Journal of Cellular Biochemistry, Supplement 20, 55-62.
11. Kelloff, G.J., Boone, C.W., Crowell, J.A., Steele, V.E., Lubet, R.A., Doody, L.A., Malone, W.F., Hawk, E.T. & Sigman, C.C. (1996) New agents for cancer chemoprevention. Journal of Cellular Biochemistry, 26S, 1-28.
12. Khan, K.N.M., Knapp, D.W., DeNicola, D.B. & Harris, R.K. (2000) Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. American Journal of Veterinary Research, 61, 478-481.
13. Knapp, D.W., Richardson, R.C., Bottoms, G.D., Teclaw, R. & Chan, T.C.K. (1992) Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemotherapy and Pharmacology, 29, 214-218.
14. Knapp, D.W., Richardson, R.C., Chan, T.C.K., Bottoms, G.D., Widmer, W.R., DeNicola, D.B., Teclaw, R. Bonney, P.L. & Kuczek, T. (1994) Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. Journal of Veterinary Internal Medicine, 8, 273-278.
15. Knapp, D.W., Chan, T.C.K., Kuczek, T., Reagan, W.J. & Park, B. (1995) Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. American Journal of Veterinary Research, 56, 801-805.
16. Knottenbelt, C.M., Simpson, J.W., Tasker, S., Ridyard, A.E., Chandler, M.L., Jamieson, P.M. & Welsh, E.M. (2000) Preliminary clinical observations on the use of piroxicam in the management of rectal tubulopapillary polyps. Journal of Small Animal Practice, 41, 393-397.
17. Lapicque, F., Netter, P., Barnwarth, B., Trechot, P., Gillet, P., Lambert, H. & Royer, R.J. (1989) Identification and simultaneous determination of non-steroidal anti-inflammatory drugs using high-performance liquid chromatography. Journal of Chromatography, 496, 301-320.
18. Lupulescu, A. (1996) Prostaglandins, their inhibitors and cancer. Prostaglandins, Leukotrienes and Essential Fatty Acids, 54, 83-94.
19. Milligan, P.A. (1992) Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by high-performance liquid chromatography. Journal of Chromatography, 576, 121-128.
20. Mohammed, S.I., Bennett, P.F., Craig, B.A., Glickman, N.W., Mutsaers, A.J., Snyder, P.W., Widmer, W.R., Degortari, A.E., Bonney, P.L. & Knapp, D.W. (2002) Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Research, 62, 356-358.
21. Okajima, E., Ozono, S., Endo, T. et al. (1997) Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and β-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl)nitrosamine treatment. Japanese Journal of Cancer Research, 88, 543-552.
22. Osweiler, G.D. (1996) Toxicology. Williams and Wilkins, PA, USA.
23. Payan, D.G. & Katzung, B.G. (1995) Nonsteroidal anti-inflammatory drugs; nonopioid analgesics; drugs used in gout. In Basic and Clinical Pharmacology, 4th edn. Ed Katzung, B.G. pp. 536-559. Appleton and Lange, CT, USA.
24. Pollard, M. & Luckert, P.H. (1989) Prevention and treatment of primary intestinal tumors in rats by piroxicam. Cancer Research, 49, 6471-6473.
25. Riviere, J.E. (1999) Comparative Pharmacokinetics: Principles, Techniques, and Applications. Iowa State University Press, Ames, IA, USA.
26. Schmidt, B.R., Glickman, N.W., DeNicola, D.B., de Gortari, A.E. & Knapp, D.W. (2001) Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association, 218, 1783-1786.
27. Sumano, H. & De Vizcaya, A.D. (1996) Tolerance and clinical evaluation of piroxicam in dogs. Canine Practice, 21, 16-19.
28. Woolf, T.F. & Radulovic, L.L. (1989) Oxicams: metabolic disposition in man and animals. Drug Metabolism Reviews, 21, 255-276.
29. Yritia, M., Parra, P., Fernandez, J.M. & Barbanoj, J. M. (1999) Piroxicam quantitation in human plasma by high-performance liquid chromatography with on- and off-line solid-phase extraction. Journal of Chromatography A, 846, 199-205.